Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
717 (USA) · Dr. Reyes
consented 2013-12-19
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild ALOPECIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-01-15 (study day 28.0); relationship: REMOTE
mild
assessed
Mild SKIN IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-19 (study day 1.0); relationship: PROBABLE
Data queries
No data queries.